- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06562322
Acute Effect of Photobiomodulation Therapy on Muscle Performance in Female Futsal Players
January 7, 2026 updated by: Andreo Fernando Aguiar, Universidade Norte do Paraná
Acute Dose-response Effect of Photobiomodulation Therapy on Muscle Performance in Female Futsal Players: a Randomized, Double-blind, Placebo-controlled, Crossover Study
Photobiomodulation therapy (PBMT) has recently been indicated as a potential therapeutic strategy in diverse health and sports contexts.
However, its efficacy on muscle performance in female futsal players remains unknown.
The purpose of this study was to investigate the dose-response effect of PBMT on muscle performance in female futsal players.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Background: Photobiomodulation therapy (PBMT) has recently been indicated as a potential therapeutic strategy in diverse health and sports contexts.
However, its efficacy on muscle performance in female futsal players remains unknown.
The purpose of this study is to investigate the dose-response effect of PBMT on muscle performance in female futsal players.
Methods: In a crossover design, fifteen female futsal athletes (age: 18-30 years) will be randomized to receive 1 of 4 PBMT conditions (placebo, 300, 900, and 1260 joules [J]) on four occasions, separated by a 2-wk washout period.
PBMT treatments will be applied on the quadriceps muscle of both legs using a device containing 200 light-emitting diodes (LEDs), immediately before the following tests (dependent variables): countermovement jump (CMJ) (i.e., flight time as indicator of muscle power), maximum voluntary isometric contraction (MVIC) for the leg extension exercise (i.e., muscle strength), and 3 sets of repetitions-to-failure (i.e., local muscular endurance) for the 45º leg press exercise, with recording of rating of perceived exertion (RPE) after each set.
The fatigue index will be determined by the number of repetitions between sets 1 and 3. Statistical analyses will be performe using IBM SPSS Statistics for Windows (version 24.0;
IBM Corp., Armonk, NY).
Data will be tested for normality and homogeneity using the Shapiro-Wilk's and Levene's tests, respectively.
One-way ANOVA tests will be performed to evaluate the differences in the fatigue index, flight time, and peak and mean torque between the treatment conditions (placebo, 300, 900, and 1260 J).
Changes over time and between treatment conditions in maximum number of repetitions and RPE will be analyzed with two-way repeated measures ANOVA.
Violation of sphericity was corrected using the Greenhouse-Geisser method.
When significant differences will be confirmed with the ANOVA, multiple comparison testing will be performed using the Bonferroni post hoc correction to identify these differences.
Values will be expressed as mean (standard deviation and 95% confidence interval).
The significance level was set at p < 0.05.
Study Type
Interventional
Enrollment (Actual)
15
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Paraná
-
Londrina, Paraná, Brazil, 86.041-140
- Universidade Norte do Paraná
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Age between 18 and 35 years
- Playing futsal regularly for more than 1 year.
Exclusion Criteria:
- Use of any ergogenic or anabolic supplement within 6 months prior to the start of the study,
- Take any medication that may affect the ability to perform the physical tests,
- Have any physical limitation (e.g. joint or muscle injury) that may affect the ability to perform the physical test,
- Be engaged in a restricted diet program (e.g. weight loss diet),
- Have any skin sensitivity or diseases (e.g. erysipelas, eczema, dermatitis, psoriasis and urticaria) in the irradiated area that may be aggravated by PBMT.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: placebo PBMT
Participants will be received placebo PBMT immediately before physical tests.
|
Participants will be received placebo PBMT on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)
|
|
Active Comparator: 300 J PBMT
Participants will be received PBMT at 300 J immediately before physical tests.
|
Participants will be received PBMT at 300 J on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)
|
|
Active Comparator: 600 J PBMT
Participants will be received PBMT at 600 J immediately before physical tests.
|
Participants will be received PBMT at 600 J on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)
|
|
Active Comparator: 1260 J PBMT
Participants will be received PBMT at 1260 J immediately before physical tests.
|
Participants will be received PBMT at 1260 J on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Countermovement vertical jump (CMJ)
Time Frame: 10 minutes
|
The CMJ test will be performed on a force platform (BIOMEC400-412, EMG System to Brazil Ltda, São Paulo, Brazil) to assess the flight time.
Participants will perform three CMJs, interspersed with 1 min of rest, and the highest flight time will be used as an indicator of muscle power.
The test will began with the participant standing, knees extended, and hands fixed on the iliac crest region (hips).
The participant then will flexed their legs at an angle of approximately 90º and then quickly extended their legs to maximize the height of the jump.
Hands will be kepted on hips throughout the jump.
|
10 minutes
|
|
Repetitions-to-failure
Time Frame: 10 minutes
|
The repetitions-to-failure test in the 45º leg press exercise consists of 3 sets at 70% of 1RM, with a 60-s rest interval between each set.
Participants will perform as many repetitions as possible until momentary failure (i.e., when the participant is unable to complete the concentric portion of their current repetition across the full range of motion despite using maximal effort), and the maximum number of repetitions in each set will be recorded.
|
10 minutes
|
|
Fatigue index (FI)
Time Frame: 10 minutes
|
The fatigue index (FI) will be determined by the equation: [(REPS3 - REPS1)/REPS1]*100, where: REPS3 = number of repetitions in set 3, multiplied by the load lifted, and REPS1 = number of repetitions in set 1, multiplied by the load lifted.
The higher the FI value (%), the higher the level of muscle fatigue.
|
10 minutes
|
|
Rating of perceive exterion (RPE)
Time Frame: 10 minutes
|
Rating of perceived exertion (RPE) will be recorded immediately after completion of each set using the OMNI-RES scale.
The participants will be instructed to report the perceived exertion value by indicating a number on the OMNI-RES scale (0 for ''no effort'' and 10 for ''maximal effort'') that best represented their momentary exertion.
|
10 minutes
|
|
Maximum voluntary isometric contraction (MVIC)
Time Frame: 10 minutes
|
The MVIC test for the leg extension exercise (bilateral) will be performed using an isometric dynamometer (CEFISE Biotechnology, São Carlos, Brazil).
Briefly, participants will perform three MVICs at 120º of knee flexion (180º = full extension) lasting 5 s, interspersed with 5 s of rest.
Participants will be instructed and verbally encouraged to exert maximum force during all attempts.
The highest value obtained for peak and mean torque of the three MVICs will be used for the analysis.
|
10 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Luque MZ, Aguiar AF, da Silva-Araujo AK, Zaninelli TH, Heintz OK, Saraiva-Santos T, Bertozzi MM, Souza NA, Junior EO, Verri WA Jr, Borghi SM. Evaluation of a preemptive intervention regimen with hesperidin methyl chalcone in delayed-onset muscle soreness in young adults: a randomized, double-blinded, and placebo-controlled trial study. Eur J Appl Physiol. 2023 Sep;123(9):1949-1964. doi: 10.1007/s00421-023-05207-2. Epub 2023 Apr 29.
- Robertson RJ, Goss FL, Rutkowski J, Lenz B, Dixon C, Timmer J, Frazee K, Dube J, Andreacci J. Concurrent validation of the OMNI perceived exertion scale for resistance exercise. Med Sci Sports Exerc. 2003 Feb;35(2):333-41. doi: 10.1249/01.MSS.0000048831.15016.2A.
- Steele J, Fisher J, Giessing J, Gentil P. Clarity in reporting terminology and definitions of set endpoints in resistance training. Muscle Nerve. 2017 Sep;56(3):368-374. doi: 10.1002/mus.25557. Epub 2017 Apr 1.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 15, 2024
Primary Completion (Actual)
March 15, 2024
Study Completion (Actual)
March 18, 2024
Study Registration Dates
First Submitted
August 16, 2024
First Submitted That Met QC Criteria
August 16, 2024
First Posted (Actual)
August 20, 2024
Study Record Updates
Last Update Posted (Actual)
January 9, 2026
Last Update Submitted That Met QC Criteria
January 7, 2026
Last Verified
August 1, 2024
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- Photobiomodulation and futsal
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Muscle Performance
-
United States Army Research Institute of Environmental...US Army Natick Soldier Research, Development & Engineering CenterCompletedMuscle Loss | Muscle Anabolism | Muscle PerformanceUnited States
-
Gümüşhane UniversıtyCompletedInspiratory Muscle Training | Jump Performance | Shooting Performance | Precision Sport PerformanceTurkey (Türkiye)
-
University of YalovaCompletedAthletic Performance | Muscle Strength | Balance | Physical PerformanceTurkey (Türkiye)
-
Muş Alparslan UniversityNot yet recruiting
-
University of BeykentCompletedAthletic Performance | Muscle Fatigue | Muscle ElasticityTurkey (Türkiye)
-
Ángel RodríguezRecruitingPerformance Measures | Jumping Performance | Isometric Muscle Strength | WeightliftingMexico
-
Ahmet MorCompletedMuscle Strength | Physical Performance | Neuromuscular Performance | Explosive PowerTurkey (Türkiye)
-
Imam Abdulrahman Bin Faisal UniversityCompletedMuscle Power PerformanceSaudi Arabia
-
Universidade Federal de Sao CarlosRecruitingAthletic Performance | Muscle Strength | Muscle Fatigue | SportsBrazil
-
University of ThessalyCompletedAthletic Performance | Muscle Damage | Skeletal Muscle DamageGreece
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AkesoNot yet recruitingAtopic DermatitisChina
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States